<DOC>
	<DOCNO>NCT00587067</DOCNO>
	<brief_summary>This phase II study aim evaluate regional chemotherapy patient unresectable primary hepatic malignancy . Specifically , eligible patient hepatocellular carcinoma peripheral cholangiocarcinoma , consider unresectable review Hepatobiliary Surgery service , undergo hepatic artery pump placement continuous infusion FUDR . The protocol include radiological biological correlative study .</brief_summary>
	<brief_title>A Phase II Study Continuous Hepatic Arterial Infusion With Floxuridine ( FUDR ) Dexamethasone ( DEX ) Patients With Unresectable Primary Hepatic Malignancy</brief_title>
	<detailed_description>This phase II study aim evaluate regional chemotherapy patient unresectable primary hepatic malignancy . Specifically , eligible patient hepatocellular carcinoma peripheral cholangiocarcinoma , consider unresectable review Hepatobiliary Surgery service , undergo hepatic artery pump placement continuous infusion FUDR . The protocol include radiological biological correlative study . The primary objective study 1 . ) ass efficacy continuous hepatic arterial infusion ( HAI ) FUDR dexamethasone ( DEX ) patient unresectable hepatocellular carcinoma ( HCC ) intrahepatic cholangiocarcinoma ( ICC ) 2 . ) ass patient tolerability therapy stratify degree underlying hepatic parenchymal disease , determine liver biopsy . Secondary objective 1 . ) use dynamic MRI evaluate change tumor perfusion treatment correlate finding radiographic tumor response 2 . ) investigate molecular genetic change associate tumor use comparative genomic hybridization cDNA array tumor liver biopsy specimen obtain time operation . All patient enrol study begin HAI FUDR 0.16 mg/kg/day . An initial cohort 12 patient enrol treat . Dose limit toxicity ( DLT ) relate FUDR define change liver function blood test unrelated disease progression mechanical biliary obstruction . Modifications FUDR dose may require . A patient consider intolerant therapy treatment must stop due DLT least first 3 month . Treatment continue long least stable disease acceptable toxicity . If , initial cohort , 4 patient ( &gt; 30 % ) intolerant therapy least 2 responder , study terminate . Otherwise , accrual continue maximum 35 patient .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients liver mass radiographically consistent HCC serum alpha fetoprotein ( AFP ) &gt; 500 ng/dl require biopsy confirmation diagnosis . Patients HCC ICC undergo exploration possible curative resection find unresectable disease confine liver eligible , provide intraoperative finding would exclude prior inform consent obtain ( see ) . There must &lt; 70 % liver involvement cancer , disease must consider unresectable . Patients fail ablative therapy eligible . Patients must KPS &gt; 60 % consider candidate general anesthesia hepatic artery pump placement . Patients chronic hepatitis and/or cirrhosis eligible Serum albumin must &gt; 2.5 g/dl total serum bilirubin must &lt; 1.8 mg/dl base preoperative laboratory value within 14 day registration . WBC must &gt; 3500 cells/mm3 platelet count must &gt; 100,000/mm3 base preoperative laboratory value within 14 day registration . The international normalized ratio ( INR ) must less 1.5 patient coumadin therapy , base preoperative laboratory value within 14 day registration . Age &gt; _ 18 year . Female patient pregnant lactate . Patients must able understand sign inform consent . Patients receive prior treatment FUDR Patients prior external beam radiation therapy liver . Patients diagnosis sclerosing cholangitis . Patients diagnosis Gilbert 's disease . Patients clinical ascites Patients hepatic encephalopathy Patients radiographic evidence esophageal varix history variceal hemorrhage . Patients occlusion main portal vein right leave portal branch Patients concurrent malignancy ( except localize basal cell squamous cell skin cancer ) . Patient active infection . Female patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>FUDR</keyword>
	<keyword>FLOXORUIDINE</keyword>
	<keyword>DEXAMETHASONE</keyword>
	<keyword>Hepatic</keyword>
	<keyword>Cancer</keyword>
	<keyword>02-120</keyword>
</DOC>